Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, its clear that bio/pharma companies would rather make than buy.
According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.
– Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
– It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
– It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=903182
Reasons to buy
– The 16-page report provides important insight that you wont find in any other source. This report is required reading for –
– CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
– Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Table of Contents
Executive Summary 1
CapEx Overview 3
CapEx Relative to Other Financial Indicators 6
Nature of Capital Expenditure – What Is Being Built 8
What It Means 10
Recently Announced and Completed Investments by Global Bio/Pharma Companies 12
Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies 14
Selected CapEx Investments by Generic Companies 2014 Onwards 15
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=903182